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Abstract
Background: Studies have shown that surgery alone is less than satisfactory in the management of early gastric 
cancer, with cure rates approaching 40%. The role of adjuvant therapy was indefinite until three large, randomized 
controlled trials showed the survival benefit of adjuvant therapy over surgery alone. Chemoradiation therapy has been 
criticized for its high toxicity.
Methods: 24 patients diagnosed between September 2001 and July 2007 were treated with adjuvant chemoradiation. 
18 patients had the classical MacDonald regimen of 4500 cGy of XRT and chemotherapy with 5-fluorouracil (5FU) and 
leucovorin, while chemotherapy consisted of 5FU/Cisplatin for 6 patients.
Results: This series consisted of non-metastatic patients, 17 females and 7 males with a median age of 62.5 years. 23 
patients (96%) had a performance status of 0 or 1. The full course of radiation therapy (4500 cGy) was completed by 22 
patients (91.7%). Only 7 patients (36.8%) completed the total planned courses of chemotherapy. 2 local relapses (10%), 
2 regional relapses (10%) and 2 distant relapses (10%) were recorded. Time to progression has not been reached. 9 
patients (37.5%) died during follow-up with a median overall survival of 75 months. Patients lost a mean of 4 Kgs during 
radiation therapy. We recorded 6 episodes of febrile neutropenia and the most frequent toxicity was gastro-intestinal in 
17 patients (70.8%) with 9 (36%) patients suffering grade 3 or 4 toxicity and 5 patients (20%) suffering from grade 3 or 4 
neutropenia. 4 (17%) patients required total parenteral nutrition for a mean duration of 20 days. 4 patients suffered 
septic shock (17%) and 1 patient developed a deep venous thrombosis and a pulmonary embolus.
Conclusions: Adjuvant chemo-radiation for gastric cancer is a standard at our institution and has resulted in few 
relapses and an interesting median survival. Toxicity rates were serious and this remains a harsh regimen with only 
36.8% of patients completing the full planned courses of chemotherapy. This is due to hematological toxicity, mainly 
febrile neutropenia. This should prompt us to review the subsequent chemotherapy protocol and make it more 
tolerable.
Background
While gastric cancer incidence is second only to lung
cancer worldwide, with an estimated 870,000 new cases
and 650,000 deaths every year and the high-risk areas
being East Asia, South America, and Eastern Europe
[1,2], the age standardized incidence rate in Lebanon
between 1998 and 2002 is 7 per 100 000 for men and 4.6
per 100 000 for women [2]. Gastric cancer constituted
5.1% of all cancer cases in Lebanon in the first national
population-based registry in 1998 [3]. The curative treat-
m e n t  o f  g a s t r i c  c a n c e r  r e q u ires surgical resection [4].
Nevertheless, studies have shown that surgery alone is
less than satisfactory with cure rates approaching 40% [5].
Worldwide, large amounts of resources have been
expended in the search for an effective adjuvant therapy
to reduce the risk of relapse following surgery for gastric
cancer. After several decades of investigation that have
yielded little improvement in survival rates, three large,
randomized controlled trials showed the survival benefit
of adjuvant therapy over surgery alone. In 2001, the
American INT 0116 demonstrated that chemoradiother-
apy after resection for gastric cancer significantly
improves relapse-free and overall survival [6]. Adjuvant
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chemoradiotherapy has been adopted since as standard
of care in the USA. Nevertheless, it is still uncommonly
used in other countries such as Britain. This relates
mainly to criticism of the INT0116 trial with regards to
suboptimal surgery, toxicity, an outdated chemotherapy
regimen and suboptimal radiotherapy techniques. Subse-
quently, the final results of The Medical Research Council
MAGIC study on perioperative chemotherapy [7] pro-
voked thoughtful discussion regarding the relative effi-
cacy of neoadjuvant chemotherapy compared with
INT0116 chemoradiation after surgery. Both studies
assessed the benefits of adjuvant therapy after only lim-
ited surgery. The Adjuvant Chemotherapy Trial of TS-1
for Gastric Cancer (ACTS-GC) showed a survival benefit
of S1 adjuvant monotherapy after curative D2 surgery in
patients with stage II or III gastric cancer [8]. Several
investigations have been made regarding the optimal che-
motherapy regimen in order to improve treatment effi-
cacy and reduce its toxicity. Moreover, the wide
availability of 3-dimensional treatment planning systems
and the technological developments in the delivery of
radiation therapy, promises improvements in the thera-
peutic ratio as well as a potential to reduce treatment-
related toxicity. This paper reports the results and toxic-
ity profile of adjuvant chemoradiation experience at the
radiation oncology department of Hotel-Dieu de France
University Hospital in Beirut, Lebanon.
Methods
T h i s  i s  a  r e t r o s p e c t i v e  a n a l y s i s  o f  a  s e r i e s  o f  p a t i e n t s
recruited from the database of the radiation oncology
department of Hotel-Dieu de France University Hospital
in Beirut Lebanon. Between September 2001 and July
2007, 24 patients with pathologically confirmed adeno-
carcinoma of the gastro-oesophageal junction or the
stomach underwent surgery with curative intent and
were treated with adjuvant chemoradiation. These
patients were treated and included in the database only if
they met the following criteria. All the patients had their
tumor staged according to the 6th edition of the American
Joint Commission on Cancer (AJCC) Cancer Staging
Manual, and metastatic patient were excluded. An East-
ern Cooperative Oncology Group (ECOG) performance
status had been recorded for all the patients. The eligibil-
ity criteria for treatment included a serum creatinine
(mg/dL) ≤ 1.5, total bilirubin ≤ 1.5 mg/dL, and alanine
aminotransferase (ALT) ≤ 1.5 × upper limit of normal.
Patients in the study did not receive preoperative chemo-
therapy. Treatment was begun as soon as possible and not
later than 8 weeks after surgery. The pretreatment evalu-
ations included physical examination, tumor markers and
computed tomography (CT) to rule out metastatic dis-
ease.
18 patients received from the classical MacDonald regi-
men of radiation therapy (XRT) and chemotherapy with
5-fluorouracil and leucovorin (5FU/LV), while chemo-
therapy consisted of 5FU/Cisplatin for 6 patients for the
same duration of treatment (5FU: 800 mg/m2 d1-d5/cis-
platin 75 mg/m2 d2).
Radiotherapy was delivered following the recommen-
dations outlined in INT0116 [6].
All patients were treated using a standardized 3D con-
formal technique. When available, the preoperative and
postoperative scans were reviewed and endoscopy, surgi-
cal, and pathology reports were also reviewed. Patients
had a CT simulation performed at least 1 week before
starting radiotherapy. The CT simulation slice thickness
was 5 mm. Patients were scanned in the supine position
with arms above their head. A total radiation dose of 45
Gy was delivered in 25 fractions at 1.8 Gy per fraction,
five days per week over five weeks. Dose variation in the
planning target volume (PTV) was kept within +7 and -
5% of the prescribed dose in accordance with ICRU 50/62
recommendations. Radiation was delivered using 6-18
MV photons with a linear accelerator. The clinical target
volume (CTV) and the design of the radiation treatment
fields were individualized depending upon the extent and
location of the primary tumor and involved lymph nodes,
and the type of surgery performed. Lymph node stations
in the radiation fields included perigastric, coeliac,
splenic hilar, suprapancreatic, porta hepatis, pancreati-
coduodenal and local paraaortic nodes. In patients with
tumors of the gastroesophageal junction, paracardial and
paraesophageal lymph nodes were included in the radia-
tion fields, but pancreaticoduodenal radiation was not
required. The planning target volume consisted of the
CTV with a 1cm margin. The organs at risk were con-
toured, which included kidneys, liver, heart, and spinal
cord. At least two third of one kidney was spared. Not
more than 50% of the heart received more than 40 Gy and
not more than 70% of the liver received more than 30 Gy.
The maximum spinal cord dose was less than 45 Gy. The
dose-volume histogram was used to ensure that the dose
tolerances were met for the nearby critical organs.
Acute toxicity data were graded according to the RTOG
Acute Radiation Morbidity Scoring Criteria [9], while
hematologic toxicity was graded using NCI-CTC version
3. Postoperative follow-up by the treating oncologist was
scheduled every 4 months for the first 2 years and every 6
months after 2 years. Follow-up included detailed history
taking and physical examination. No routine endoscopy
nor CT scans (chest, abdomen, pelvis) were done unless
clinically warranted while patients were followed with
routine CBC, chemistry and CA 19-9 at every follow-up
(as per GAST-5 NCCN guidelines). Sites of first failure
(ie, locoregional or distant) were also collected.Aftimos et al. Radiation Oncology 2010, 5:50
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Locoregional recurrence was defined as any recurrence
in the tumor bed, anastomosis site, gastric remnant, duo-
denal stump, and regional nodes within the irradiated
volume.
Distant metastases were defined as any recurrence out-
side of the irradiated field, including metastases to the
liver, lower para-aortic lymph nodes, and extra-abdomi-
nal sites and peritoneal seeding. Time to progression was
measured from the date of radical surgery to the date of
first recurrence of disease. Overall survival was also
recorded from the date of radical surgery till death from
any cause.
The data were analyzed using SPSS version 11.0.
Patient survival was calculated using the method of
Kaplan-Meier.
Results
The cohort consisted of 24 patients, 17 males and 7
females. Patient and tumor characteristics are outlined in
Tables 1. The mean age was 58.3 years (range, 35-80) and
median age was 62.5. 23 patients (96%) had a perfor-
mance status (PS) of 0 or 1. Thirteen (54%) underwent
subtotal gastrectomy and 11 had total gastrectomy (46%).
Twenty-three patients (96%) had negative margins. One
patient had infiltrated surgical margins. Stage of disease
was IB in 2 patients (8.3%), II in 9 patients (37.5%), IIIA in
8 patients (33.3%), IIIB in 4 patients (16.4%) and IV (no
metastasis) in 1 patient (4.2%). The majority of patients
(75%) had T3 primary tumors. Seventeen patients (71%)
had regional nodal involvement. 21 patients had a D1
nodal clearance and 3 patients had D2 surgery.
The median follow-up was 11.5 months and mean fol-
low-up 21.2 months. 6 patients were lost to follow-up.
The full course of radiation therapy (4500 cGy) was
completed by 22 patients (91.7%) with 1 patient continu-
ing it at a foreign institution and 1 patient interrupting it
for grade IV gastro-intestinal toxicity. Only 7 patients
(36.8%) completed the total planned courses of chemo-
therapy, 4 patients that received 5FU/LV and 3 patients
that received 5FU/cisplatin. Acute toxicity was recorded
during the concurrent chemoradiation regimen and for
the entire adjuvant chemotherapy cycles. It is described
in table 2. The most common severe acute adverse effect
was gastrointestinal in 17 patients (70.8%) with 36% grade
3 or 4 toxicity. Mucositis came in second with 32% grade
3 or 4 toxicity. Hematologic toxicity was the third major
toxicity with 20% of patients developing grade 3 or 4 neu-
tropenia and 16% of patients suffering from grade 3 or 4
anemia. 6 episodes of febrile neutropenia were recorded.
Patients lost a mean of 7% of body weight during radia-
tion therapy. 25% of patients lost 10% or more of body
weight while 45% of patients lost between 5 and 10% of
their initial body weight during radiation therapy. 4 (17%)
patients required total parenteral nutrition for a mean
duration of 20 days (range 3-60 days). 4 patients suffered
septic shock (17%) and 1 patient developed a deep venous
thrombosis and a pulmonary embolus. Toxicity pattern in
patients receiving 5FU and cisplatin (n = 6) was compara-
ble to the entire cohort: 50% grade 3 or 4 gastrointestinal
toxicity, 33% grade 3 or 4 mucositis, 33% grade 3 or 4
neutropenia, 33% grade 3 or 4 anemia.
Among 24 patients in the entire cohort, 4 patients
(22%) relapsed with disease during the follow-up period.
The patterns of failure are described in table 3. Two
patients had an isolated locoregional recurrence, and 2
relapsed with both locoregional and distant disease. All of
the patients who relapsed had negative pathologic mar-
gins. The median time to relapse from the end of the radi-
ation was 10.5 months (range 5-18).
18 patients were followed-up for survival. In the entire
cohort, the median survival was 75 months while time to
progression has not been reached (Figs.1 and 2). 9
patients (37.5%) died during follow-up. All 4 patients that
experienced relapse died. 5 patients died in remission, 4
of which were considered toxic deaths: one with a mas-
sive pulmonary embolus, one from extreme cachexia and
three from septic shock.
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Discussion
The five-year survival rate for patients with completely
resected early gastric cancer is approximately 75 percent
[10], while it is 30 percent or less for patients who have
extensive lymph node involvement [11]. A Dutch ran-
domized trial published in 1999 did not support the rou-
t i n e  u se  o f  D 2  o v e r  D 1  l ym p h a d e n ect o m y  i n  t e r m s  o f
survival [12]. These sobering results have spawned efforts
to improve the treatment results for this group of patients
using adjuvant or neoadjuvant radiation therapy and/or
chemotherapy.
The major risk factors for stomach cancer are hypothe-
sized to be nutritional [13]. The Middle East has good
access to fruits and vegetables throughout the year, and
the nutritional practices have Mediterranean influences.
This may result in the low incidence rates that were
observed. However, smoking carries a slightly increased
risk for stomach cancer [14] and smoking is quite com-
mon in countries of the Middle East.
The favored adjuvant strategy at our institution is the
Intergroup trial 0116 chemoradiotherapy regimen. Our 7
years experience seems commensurate with that of INT-
0116. The treated population has similar characteristics:
median age was 62.5 years old comparable to 60 in the
chemoradiotherapy group of INT-0116. Stomach cancer
is among those cancers that are more difficult to detect,
and is mostly diagnosed at a later stage. 75% of patients in
our series had T3 tumors, as were the majority in INT-
0116 with 68 and 69% of T3-T4 in the treated and control
groups respectively. Nodal status demonstrates advanced
disease with 85% positive in INT-0116. 70% of patients in
this described series had positive nodes. Our results how-
ever are incomparable for the main reason that this series
is retrospective and descriptive of only 24 patients while
INT-0116 is a prospective randomized study of 556
patients. Second, the follow-up period and the little num-
ber of events only allowed a median survival analysis
while time to progression has not yet been reached. This
retrospective work has helped us evaluate our chosen
institutional adjuvant gastric cancer strategy in terms of
relapse and survival. We have specially learned from the
criticism of the American Intergroup trial about the lim-
ited extent of the surgical procedure in many cases. Being
a multi-centre trial with the lack of monitoring of the
quality of surgery, D2 lymph node dissection was only
performed in 10% of the enrollees, and 54% did not even
have clearance of the D1 nodal regions. Gastric oncologic
surgery at our institution is performed by one academic
Table 2: Acute toxicity
Grade 1 Grade 2 Grade 3 Grade 4 Grade 3 & 4
A d v e r s e  E v e n t s n%n%n%n%n%
M u c o s i t i s 0 0 . 0 0 0 . 0 31 2 . 052 0 . 083 2 . 0
G I 31 2 . 052 0 . 02 8 . 0 72 8 . 093 6 . 0
Neutropenia 3 12.0 3 12.0 1 4.0 4 16.0 5 20.0
Anemia 5 20.0 5 20.0 4 16.0 0 0.0 4 16.0
T h r o m b o c y t o p e n i a 4 1 6 . 0 14 . 014 . 000 . 014 . 0
D e r m a t i t i s 00 . 000 . 014 . 000 . 014 . 0
Table 3: Patterns of failure
N%
Local Relapse (N = 18)
Yes 2 11.0
No 16 89.0
Regional Relapse (N = 18)
Yes 2 11.0
No 16 89.0
Distant Relapse (N = 18)
Yes 2 11.0
No 16 89.0Aftimos et al. Radiation Oncology 2010, 5:50
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Figure 1 overall survival curve.
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surgeon and negative gastrectomy margins with D1 nodal
dissection or more have been implemented as a require-
ment for enrollment in the chemoradiotherapy regimen.
All patients in the described series had therefore bene-
fited from D1 or D2 resection.
However, toxicity remains a problem and this regimen
is harsh on patients. Historically peri-operative morbidity
and mortality are 25% and 4% respectively for D1 resec-
tion, and 43% and 10% respectively for D2 resection [4].
36% of patients of the chemoradiotherapy arm of INT-
0116 did not complete the regimen while grade 3 and
grade 4 toxic effects occurred in 41 and 32% of cases
respectively. While most of our patients (91.7%) managed
to go through the full radiation therapy course, more than
half (63.2%) didn't complete the whole treatment plan
with a mean weight loss of 4 kilograms between the
beginning and end of treatment. Even though worse and
most frequent adverse events were, as in INT-0116, gas-
tro-intestinal and hematological, the rate of serious toxic-
ity in this described series is high. 4 toxic deaths have
been counted (17%) compared to only 1% in INT-
0116.The numbers of grade 3 or 4 neutropenia (20%) and
septic shocks (17%) need to be considered. This should
prompt us to evaluate other adjuvant strategies, the
MAGIC regimen notably [7] or other treatment delivery
strategies: postoperative chemoradiation in combination
with preoperative chemotherapy (CRITICS trial: Clini-
caltrials.gov NCT 00407186), the role of adding bevaci-
zumab to perioperative chemotherapy (MAGIC-B study:
MRC-ST03).
Conclusions
The results of adjuvant chemoradiotherapy have changed
the standard of care in the US following potentially cura-
tive resection of gastric cancer. Even more, support for
the benefit of adjuvant chemoradiotherapy in patients
who have undergone a therapeutic D2 lymph node dis-
section was provided by a retrospective review of 990
Korean patients whose 5-year overall survival and
relapse-free survival rates significantly favor chemoradio-
therapy [15]. The optimal regimen for postoperative
chemoradiotherapy has not yet been established. The
future research is on optimizing the chemotherapy regi-
men, defining the role of radiotherapy, it's integration in
the treatment schema (pre or postoperative) and explor-
ing the effect of treatment timing (preoperative, postop-
erative or both). Moreover, targeted therapies have
recently made their way in gastric cancer with the
approval of trastuzumab for the treatment of HER-2 posi-
tive metastatic gastric cancer [16] Anti-angiogenics (bev-
acizumab) and anti-EGFR agents (cetuximab) are also
being studied in the adjuvant setting. Future questions
arise on the role of these therapies in the adjuvant setting.
Would their inclusion in adjuvant chemotherapy regi-
mens surpass the need for radiation therapy?
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